Literature DB >> 31815761

Overexpressed CXCR4 and CCR7 on the surface of NK92 cell have improved migration and anti-tumor activity in human colon tumor model.

Lili Yang1, Changxin Huang1, Congjie Wang2, Siyu Zhang2, Zhaoyang Li1, Ying Zhu3, Da Li4, Lanlan Gao5, Zuanmin Ge5, Meng Su6, Xi Feng5, Yongqiang Li7.   

Abstract

Successive infusion of natural killer cells is increasingly being explored as a treatment for cancer patients. The inadequate homing of natural killer cells into the tumor site resulted in the poor efficacy of natural killer cells on solid tumors. For the adoptive transfer of tumor-directed natural killer cell has been proved effective, it is hypothesized that there must be more association between the tumor-produced chemokines and the natural killer cells-expressed chemokine receptors. Increased CXCL12 and CCL21 could ameliorated colorectal cancer via generating an anti-tumor environment by preferentially attracting natural killer cells which expressed the chemokine receptor CXCR4 and CCR7. This study demonstrated that overexpressed CXCR4 and CCR7 on the surface of NK92 cell enhanced their migration to human colon cells. Moreover, the administration of such natural killer cells resulted in tumor shrinkage and a significantly increased survival of experimental mice when compared to ones undergoing the treatment of xenografts with natural killer cells expressing only the mock control. These suggested that chemokine receptor engineered natural killer cells could be a promising tool to improve adoptive tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31815761     DOI: 10.1097/CAD.0000000000000868

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  2 in total

1.  Immunoregulation of Ghrelin in neurocognitive sequelae associated with COVID-19: an in silico investigation.

Authors:  Cristina Russo; Giovanna Morello; Giuliana Mannino; Antonella Russo; Lucia Malaguarnera
Journal:  Gene       Date:  2022-06-06       Impact factor: 3.913

Review 2.  Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy.

Authors:  Mubin Tarannum; Rizwan Romee; Roman M Shapiro
Journal:  Front Immunol       Date:  2022-03-25       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.